Effect of NMDA NR2B antagonist on neuropathic pain in two spinal cord injury models

Youngkyung Kim, Hwi Young Cho, Young Ju Ahn, Junesun Kim, Young Wook Yoon

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

N-Methyl-d-aspartate (NMDA) receptors are thought to play an important role in the processes of central sensitization and pathogenesis of neuropathic pain, particularly after spinal cord injury (SCI). NMDA antagonists effectively reduce neuropathic pain, but serious side effects prevent their use as therapeutic drugs. NMDA NR2B antagonists have been reported to effectively reduce inflammatory and neuropathic pain. In this study, we investigated the effects of NR2B antagonists on neuropathic pain and the expression of NR2B in the spinal cord in 2 SCI models. SCI was induced at T12 by a New York University impactor (contusion) or by sectioning of the lateral half of the spinal cord (hemisection). Ifenprodil (100, 200, 500, 1000 nmol) and Ro25-6981 (20, 50, 100, 200 nmol) were intrathecally injected and behavioral tests were conducted. Ifenprodil increased the paw withdrawal threshold in both models but also produced mild motor depression at higher doses. Ro25-6981 increased the mechanical nociceptive threshold in a dose-dependent manner without motor depression. NR2B expression was significantly increased on both sides at the spinal segments of L1-2 and L4-5 in the hemisection model but did not change in the contusion model. Increased expression of NR2B in the hemisection model was reduced by intrathecal ifenprodil. These results suggest that intrathecal NMDA NR2B antagonist increased the mechanical nociceptive threshold after SCI without motor depression. A selective subtype of NMDA receptor, such as NR2B, may be a more selective target for pain control because NMDA receptors play a crucial role in the development and maintenance of chronic pain.

Original languageEnglish
Pages (from-to)1022-1029
Number of pages8
JournalPain
Volume153
Issue number5
DOIs
Publication statusPublished - 2012 May 1

Fingerprint

Neuralgia
Spinal Cord Injuries
Aspartic Acid
Contusions
Depression
Spinal Cord
Central Nervous System Sensitization
Therapeutic Uses
Chronic Pain
Maintenance
Pain
Pharmaceutical Preparations
aspartic acid receptor
ifenprodil
Ro 25-6981

Keywords

  • Neuropathic pain
  • NMDA NR2B
  • NR2B antagonists
  • Spinal cord injury

ASJC Scopus subject areas

  • Clinical Neurology
  • Anesthesiology and Pain Medicine
  • Neurology
  • Pharmacology

Cite this

Effect of NMDA NR2B antagonist on neuropathic pain in two spinal cord injury models. / Kim, Youngkyung; Cho, Hwi Young; Ahn, Young Ju; Kim, Junesun; Yoon, Young Wook.

In: Pain, Vol. 153, No. 5, 01.05.2012, p. 1022-1029.

Research output: Contribution to journalArticle

Kim, Youngkyung ; Cho, Hwi Young ; Ahn, Young Ju ; Kim, Junesun ; Yoon, Young Wook. / Effect of NMDA NR2B antagonist on neuropathic pain in two spinal cord injury models. In: Pain. 2012 ; Vol. 153, No. 5. pp. 1022-1029.
@article{8ed917a8c2be4621a07fcea42f27988a,
title = "Effect of NMDA NR2B antagonist on neuropathic pain in two spinal cord injury models",
abstract = "N-Methyl-d-aspartate (NMDA) receptors are thought to play an important role in the processes of central sensitization and pathogenesis of neuropathic pain, particularly after spinal cord injury (SCI). NMDA antagonists effectively reduce neuropathic pain, but serious side effects prevent their use as therapeutic drugs. NMDA NR2B antagonists have been reported to effectively reduce inflammatory and neuropathic pain. In this study, we investigated the effects of NR2B antagonists on neuropathic pain and the expression of NR2B in the spinal cord in 2 SCI models. SCI was induced at T12 by a New York University impactor (contusion) or by sectioning of the lateral half of the spinal cord (hemisection). Ifenprodil (100, 200, 500, 1000 nmol) and Ro25-6981 (20, 50, 100, 200 nmol) were intrathecally injected and behavioral tests were conducted. Ifenprodil increased the paw withdrawal threshold in both models but also produced mild motor depression at higher doses. Ro25-6981 increased the mechanical nociceptive threshold in a dose-dependent manner without motor depression. NR2B expression was significantly increased on both sides at the spinal segments of L1-2 and L4-5 in the hemisection model but did not change in the contusion model. Increased expression of NR2B in the hemisection model was reduced by intrathecal ifenprodil. These results suggest that intrathecal NMDA NR2B antagonist increased the mechanical nociceptive threshold after SCI without motor depression. A selective subtype of NMDA receptor, such as NR2B, may be a more selective target for pain control because NMDA receptors play a crucial role in the development and maintenance of chronic pain.",
keywords = "Neuropathic pain, NMDA NR2B, NR2B antagonists, Spinal cord injury",
author = "Youngkyung Kim and Cho, {Hwi Young} and Ahn, {Young Ju} and Junesun Kim and Yoon, {Young Wook}",
year = "2012",
month = "5",
day = "1",
doi = "10.1016/j.pain.2012.02.003",
language = "English",
volume = "153",
pages = "1022--1029",
journal = "Pain",
issn = "0304-3959",
publisher = "Elsevier",
number = "5",

}

TY - JOUR

T1 - Effect of NMDA NR2B antagonist on neuropathic pain in two spinal cord injury models

AU - Kim, Youngkyung

AU - Cho, Hwi Young

AU - Ahn, Young Ju

AU - Kim, Junesun

AU - Yoon, Young Wook

PY - 2012/5/1

Y1 - 2012/5/1

N2 - N-Methyl-d-aspartate (NMDA) receptors are thought to play an important role in the processes of central sensitization and pathogenesis of neuropathic pain, particularly after spinal cord injury (SCI). NMDA antagonists effectively reduce neuropathic pain, but serious side effects prevent their use as therapeutic drugs. NMDA NR2B antagonists have been reported to effectively reduce inflammatory and neuropathic pain. In this study, we investigated the effects of NR2B antagonists on neuropathic pain and the expression of NR2B in the spinal cord in 2 SCI models. SCI was induced at T12 by a New York University impactor (contusion) or by sectioning of the lateral half of the spinal cord (hemisection). Ifenprodil (100, 200, 500, 1000 nmol) and Ro25-6981 (20, 50, 100, 200 nmol) were intrathecally injected and behavioral tests were conducted. Ifenprodil increased the paw withdrawal threshold in both models but also produced mild motor depression at higher doses. Ro25-6981 increased the mechanical nociceptive threshold in a dose-dependent manner without motor depression. NR2B expression was significantly increased on both sides at the spinal segments of L1-2 and L4-5 in the hemisection model but did not change in the contusion model. Increased expression of NR2B in the hemisection model was reduced by intrathecal ifenprodil. These results suggest that intrathecal NMDA NR2B antagonist increased the mechanical nociceptive threshold after SCI without motor depression. A selective subtype of NMDA receptor, such as NR2B, may be a more selective target for pain control because NMDA receptors play a crucial role in the development and maintenance of chronic pain.

AB - N-Methyl-d-aspartate (NMDA) receptors are thought to play an important role in the processes of central sensitization and pathogenesis of neuropathic pain, particularly after spinal cord injury (SCI). NMDA antagonists effectively reduce neuropathic pain, but serious side effects prevent their use as therapeutic drugs. NMDA NR2B antagonists have been reported to effectively reduce inflammatory and neuropathic pain. In this study, we investigated the effects of NR2B antagonists on neuropathic pain and the expression of NR2B in the spinal cord in 2 SCI models. SCI was induced at T12 by a New York University impactor (contusion) or by sectioning of the lateral half of the spinal cord (hemisection). Ifenprodil (100, 200, 500, 1000 nmol) and Ro25-6981 (20, 50, 100, 200 nmol) were intrathecally injected and behavioral tests were conducted. Ifenprodil increased the paw withdrawal threshold in both models but also produced mild motor depression at higher doses. Ro25-6981 increased the mechanical nociceptive threshold in a dose-dependent manner without motor depression. NR2B expression was significantly increased on both sides at the spinal segments of L1-2 and L4-5 in the hemisection model but did not change in the contusion model. Increased expression of NR2B in the hemisection model was reduced by intrathecal ifenprodil. These results suggest that intrathecal NMDA NR2B antagonist increased the mechanical nociceptive threshold after SCI without motor depression. A selective subtype of NMDA receptor, such as NR2B, may be a more selective target for pain control because NMDA receptors play a crucial role in the development and maintenance of chronic pain.

KW - Neuropathic pain

KW - NMDA NR2B

KW - NR2B antagonists

KW - Spinal cord injury

UR - http://www.scopus.com/inward/record.url?scp=84862792334&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862792334&partnerID=8YFLogxK

U2 - 10.1016/j.pain.2012.02.003

DO - 10.1016/j.pain.2012.02.003

M3 - Article

VL - 153

SP - 1022

EP - 1029

JO - Pain

JF - Pain

SN - 0304-3959

IS - 5

ER -